Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jiaping Ni"'
Autor:
Chen Wang, Jiaping Ni, Dongqing Zhai, Yanchao Xu, Zijie Wu, Yuyuan Chen, Ning Liu, Juan Du, Yumeng Shen, Guilai Liu, Yong Yang, Linjun You, Weiwei Hu
Publikováno v:
Experimental and Molecular Medicine, Vol 56, Iss 5, Pp 1150-1163 (2024)
Abstract Hepatocellular carcinoma (HCC) is associated with a poor prognosis. Our previous study demonstrated that Pleomorphic adenoma gene like-2 (PLAGL2) was a potential therapeutic target in HCC. However, the mechanisms that lead to the upregulatio
Externí odkaz:
https://doaj.org/article/23073bf205194891b14ec7db47f93832
Publikováno v:
Cellular and Molecular Life Sciences. 79
Chronic stress activates the sympathetic nervous system (SNS) and hypothalamic-pituitary-adrenal (HPA) axis to aggravates tumorigenesis and development. Although the importance of SNS and HPA in maintaining homeostasis has already attracted much atte
Autor:
Beiying Dai, Hongbao Yang, Jifeng Feng, Yaohong Shi, Decai Yu, Lanxin Li, Jiaping Ni, Duowei Wang, Guilai Liu, Amir Hossain, Mo Wu, Weiwei Hu, Lutz Birnbaumer, Yong Yang, Hanrui Bian, Yumeng Shen, Shufang Zheng, Haixin Guo, Zhoutong Tian, Qin Zhang, Jun Yu
Publikováno v:
Hepatology. 73:674-691
Background and aims Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, hence a major public health threat. Pleomorphic adenoma gene like-2 (PLAGL2) has been reported to play a role in tumorigenesis. However,
Autor:
Tianle Jin, Weiwei Hu, Yuchen Yao, Zhuo Wang, Shufang Zheng, Ying Li, Hongxi Wu, Mingying Lu, Ansheng Yuan, Zhen Chen, Yong Yang, Haixin Guo, Meng Jiao, Jiaping Ni, Haoying Zhang
Publikováno v:
Pharmacological Research. 169:105685
Erlotinib, an EGFR tyrosine kinase inhibitor has been introduced into cancer chemotherapy. However, the therapeutic effects of erlotinib in hepatocellular carcinoma (HCC) remain vaguely understood. Our previous study found that a hypoxia-mediated PLA